Dowling-Meara Epidermolysis Bullosa SimplexSymptoms, Doctors, Treatments, Advances & More
Dowling-Meara Epidermolysis Bullosa Simplex Overview
Learn About Dowling-Meara Epidermolysis Bullosa Simplex
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dermatologists Of Southwest Ohio, Inc.
Anne Lucky is a Dermatologist in Cincinnati, Ohio. Dr. Lucky is rated as an Elite provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Lucky is currently accepting new patients.
Catherine Laprise practices in Saguenay, Canada. Ms. Laprise is rated as an Elite expert by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, Asthma, and Epidermolysis Bullosa.
Cristina Has practices in Freiburg, Germany. Ms. Has is rated as an Elite expert by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, and Junctional Epidermolysis Bullosa.
Summary: The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Summary: This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (4 years of age and older) diagnosed with generalized intermediate to severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily appli...